Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · IEX Real-Time Price · USD
42.73
+1.06 (2.54%)
At close: Jul 19, 2024, 4:00 PM
42.72
-0.01 (-0.02%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Xenon Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for XENE stock have an average target of 59, with a low estimate of 50 and a high estimate of 65. The average target predicts an increase of 38.08% from the current stock price of 42.73.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 18, 2024.
Analyst Ratings
The average analyst rating for XENE stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $55 | Buy | Reiterates | $55 | +28.72% | Jun 18, 2024 |
| Needham | Needham | Strong Buy Maintains $62 | Strong Buy | Maintains | $62 | +45.10% | May 10, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $62 → $60 | Strong Buy | Maintains | $62 → $60 | +40.42% | May 10, 2024 |
| Wedbush | Wedbush | Buy Maintains $51 → $50 | Buy | Maintains | $51 → $50 | +17.01% | May 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $62 | Strong Buy | Reiterates | $62 | +45.10% | Apr 12, 2024 |
Financial Forecast
Revenue This Year
2.04M
Revenue Next Year
10.22M
from 2.04M
Increased by 400.74%
EPS This Year
-2.96
from -2.73
EPS Next Year
-3.31
from -2.96
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.3M | 78.8M | 113.5M | 961.7M | 1.3B |
| Avg | 2.0M | 10.2M | 67.3M | 340.5M | 620.3M |
| Low | n/a | n/a | 14.7M | 68.6M | 294.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 3,760.3% | 1,011.4% | 1,328.5% | 289.1% |
| Avg | - | 400.7% | 559.0% | 405.8% | 82.2% |
| Low | - | - | 43.9% | 1.9% | -13.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.67 | -1.17 | -1.85 | 1.90 | 4.73 |
| Avg | -2.96 | -3.31 | -3.46 | -1.40 | 0.87 |
| Low | -3.33 | -4.15 | -4.57 | -2.72 | -1.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.